Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate cancer that continues to grow despite having very low testosterone levels (known as castration resistant prostate cancer), confirmed through a tissue or cell sample.
- People who are reasonably active in daily life and able to care for themselves, with a general health score of 0–2 on a standard medical scale, and who are expected to live at least 6 more months.
- People whose bone marrow, kidneys, and liver are functioning at an adequate level.
Who may not be able to join:
- People who have previously had radiation treatment covering more than 25% of their bone marrow.
- People whose heart's electrical activity shows a specific measurement (called QTcF interval) above 480 milliseconds on a heart tracing test at the start of the trial.
- People who have high blood pressure that remains above 150/90 mmHg even with the best available medication to control it.
- People with a known or suspected allergy or sensitivity to either of the study drugs (PF-06821497 or enzalutamide) or any of their ingredients.
- People with active inflammatory bowel disease, ongoing chronic diarrhoea, known pouching of the bowel wall (diverticular disease), or who have previously had stomach removal surgery or weight-loss band surgery on the stomach.
- People who are currently taking, or are expected to need, certain foods or medicines that are known to strongly or moderately affect how the body processes a specific group of drugs (called CYP3A4/5 inducers or inhibitors) (confirm with trial site).
- People who have taken enzalutamide within the 4 weeks before joining the trial.
- For a specific sub-study within the trial, additional restrictions apply, including: a history of heart failure or signs of reduced heart function; an inherited inability to digest fructose (a type of sugar); or currently taking certain medicines that are processed through the same pathway as one of the study drugs (CYP3A4 substrates) (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD); Overall safety profile including adverse events; Preliminary efficacy determination as evaluated by disease specific response criteria; Overall safety profile including laboratory abnormalities; Overall safety profile including vital signs; Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.